Tuberculosis: vaccines in the pipeline (Q37194790)

18 August 2017

1 reference

title

Tuberculosis: vaccines in the pipeline (English)

1 reference

18 August 2017

0 references

Lan H Ly

1

1 reference

18 August 2017

David N McMurray

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Expert Review of Vaccines

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

635-650

1 reference

Stopping routine vaccination for tuberculosis in schools

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis control in the era of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis Risk and Prevention in Travelers-What about BCG?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis risk in US Peace Corps Volunteers, 1996 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis: vaccine and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis vaccines - an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis vaccine development; from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

The contribution of immunology to the rational design of novel antibacterial vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4 memory T lymphocyte populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Development of new tuberculosis vaccines: a global perspective on regulatory issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

A review of vaccine research and development: tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Current status of TB vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Prime-boost immunisation strategies for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Recombinant BCG vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Improved protection by recombinant BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

The use of mutant mycobacteria as new vaccines to prevent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Failure of a Mycobacterium tuberculosis DeltaRD1 DeltapanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

DNA vaccines for therapy of tuberculosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8 T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

TB subunit vaccines--putting the pieces together

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis subunit vaccines: from basic science to clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Mycobacterial heat shock proteins as vaccines - a model of facilitated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Drying a tuberculosis vaccine without freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

The Development and Impact of Tuberculosis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

Has BCG attenuated to impotence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.7.5.635

21 January 2018

Identifiers

DOI

10.1586/14760584.7.5.635

1 reference

18 August 2017

1 reference